Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Damian J. Green, MD, Margot Pont, PhD, Andrew J. Cowan, MD, Gabriel O Cole, Blythe Duke Sather, PhD, Anne M Nagengast, RN, Xaoling Song, Sushma Thomas, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2019) 134 (Supplement_1): 1856.

https://doi.org/10.1182/blood-2019-129582

Published: 2019

Journal Articles

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

David G. Coffey, MD, Ola Landgren, MD PhD, Yuexin Xu, PhD, Dickran Kazandjian, MD, Trevor J. Pugh, PhD, Sacha Gnjatic, PhD, Edus H. Warren, MD PhD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 4367.

https://doi.org/10.1182/blood-2019-126222

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Damian J. Green, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Andrew J. Cowan, MD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent Wood, MD PhD, Michelle Blake, PhD, Melissa Works, PhD, Bruce S Thompson, PhD, Ted Gooley, PhD, Frederick R. Appelbaum, MD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2018) 132 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2018-99-117729

Published: 2018

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Shyril O'Steen, PhD, Melissa C. Comstock, BS, Johnnie J. Orozco, MD PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Jon Jones, BS, Aimee Kenoyer, BS, Margaret E. Nartea, BS, Yukang Lin, PhD, Brian W. Miller, PhD, Sherilyn A. Tuazon, MD, Brian G. Till, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, Oliver W. Press, MD PhD, Damian J. Green, MD

Blood (2018) 132 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2018-99-119555

Published: 2018

Journal Articles

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Andrew J. Cowan, MD, Philip A. Stevenson, MS, Noam Kopmar, MD, Edward N. Libby, III, MD, Pamela S. Becker, MD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Damian J. Green, MD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD

Blood (2018) 132 (Supplement 1): 198.

https://doi.org/10.1182/blood-2018-198

Published: 2018

Journal Articles

Improved Expansion and Function of CAR T Cell Products from Cultures Initiated at Defined CD4:CD8 Ratios

Dong Hoon Lee, B.S., Francisco Cervantes-Contreras, Sang Yun Lee, PhD, Damian J. Green, MD, Brian G. Till, MD

Blood (2018) 132 (Supplement 1): 3334.

https://doi.org/10.1182/blood-2018-99-111576

Published: 2018

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Johnnie J. Orozco, MD PhD, Aimee Kenoyer, BS, Yukang Lin, PhD, Darrell R. Fisher, PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Alexandra Hernandez, BS, Rosario Guel, Margaret E. Nartea, Shyril O'Steen, PhD, Mark D Hylarides, PhD, Brian G Till, MD, Damian J. Green, MD, Ajay K. Gopal, MD, Kelly D Orcutt, PhD, Karl Dane Wittrup, PhD, Brenda M. Sandmaier, MD, John M. Pagel, MD PhD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 1355.

https://doi.org/10.1182/blood.V130.Suppl_1.1355.1355

Published: 2017

Journal Articles

Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1813.

https://doi.org/10.1182/blood.V130.Suppl_1.1813.1813

Published: 2017

Journal Articles

Simultaneous Detection of Single Nucleotide Variants and Expression of RNA and Protein in Multiple Myeloma Bone Marrow Aspirates

David G. Coffey, MD, Katherine A. Lombardo, BS, Andrea M.H. Towlerton, BS, MaryCatherine A. Farwell, BS, Gokhan Demirkan, PhD, Gavin Meredith, PhD, Rhonda Meredith, BSc, Damian J. Green, MD, Edus H. Warren, III, MDPhD

Blood (2017) 130 (Supplement 1): 1758.

https://doi.org/10.1182/blood.V130.Suppl_1.1758.1758

Published: 2017

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Camille E. Puronen, MD, Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Brenda M. Sandmaier, MD, Mary E. Flowers, MD, Damian J. Green, MD, David G. Maloney, MD PhD, Rainer F. Storb, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 4559.

https://doi.org/10.1182/blood.V130.Suppl_1.4559.4559

Published: 2017

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas

Shyril O'Steen, PhD, Amelia Waltman, Garrett Booth, Aimee L Kenoyer, BS, Margaret Nartea, Chelsea Mullins, Yukang Lin, Sang Yun Lee, Mark D Hylarides, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Oliver W Press, MD PhD

Blood (2016) 128 (22): 467.

https://doi.org/10.1182/blood.V128.22.467.467

Published: 2016

Journal Articles

Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience

Andrew J. Cowan, MD, Mehdi Karami, PharmD, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Damian J. Green, MD, Teresa S. Hyun, MD PhD, Sherilyn Tuazon, MD, Mazyar Shadman, MD MPH, Ajay K Gopal, MD, Leona A Holmberg

Blood (2016) 128 (22): 3377.

https://doi.org/10.1182/blood.V128.22.3377.3377

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Improved Expansion and Function of CAR T Cell Products from Cultures Initiated at Defined CD4:CD8 Ratios

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma

Simultaneous Detection of Single Nucleotide Variants and Expression of RNA and Protein in Multiple Myeloma Bone Marrow Aspirates

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas

Outcome of Multiple Myeloma Patients Treated with Carrd-PACE Chemomobilization: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only